Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EVOK
stocks logo

EVOK

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
3.80M
+48.78%
--
--
4.33M
+62.99%
--
--
4.86M
+46.81%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Evoke Pharma, Inc. (EVOK) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 109.98%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+109.98%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Evoke Pharma Inc (EVOK.O) is 273.25, compared to its 5-year average forward P/E of 2.62. For a more detailed relative valuation and DCF analysis to assess Evoke Pharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
2.62
Current PE
273.25
Overvalued PE
41.65
Undervalued PE
-36.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.08
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.38
Undervalued EV/EBITDA
-0.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.25
Current PS
0.00
Overvalued PS
16.45
Undervalued PS
-5.95
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 53169.44% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 53169.44% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

EVOK News & Events

Events Timeline

(ET)
2025-11-13
07:08:54
Evoke Pharma announces Q3 earnings per share of 45 cents, compared to a loss of 94 cents in the same period last year.
select
2025-11-04 (ET)
2025-11-04
07:02:37
QOL Medical to purchase Evoke Pharma for $11.00 per share in cash
select
2025-08-26 (ET)
2025-08-26
07:05:22
Evoke Pharma and EVERSANA Enhance GIMOTI Availability Through Partnership with Omnicell
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
12-01Globenewswire
Halper Sadeh LLC Urges Shareholders of EVOK, FSFG, and BRY to Reach Out for Rights Consultation

  • Investigation of Companies: Halper Sadeh LLC is investigating Evoke Pharma, First Savings Financial Group, and Berry Corporation for potential violations of federal securities laws and breaches of fiduciary duties related to their recent sales.

  • Shareholder Rights: The firm encourages shareholders of the involved companies to learn about their rights and options, offering legal assistance on a contingent fee basis, meaning no upfront costs for legal fees.

  • Legal Support: Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, aiming to recover funds and implement corporate reforms.

  • Contact Information: Shareholders can reach out to attorneys Daniel Sadeh or Zachary Halper for free consultations regarding their legal rights and options.

[object Object]
Preview
8.5
12-01Globenewswire
Shareholder Notice: M&A Class Action Firm Ongoing Investigation into the Merger Involving TRUE, BRY, EVOK, and FSFG

  • Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.

  • TrueCar, Inc. Sale: TrueCar shareholders are set to receive $2.55 per share in cash following its sale to Fair Holdings, with a shareholder vote scheduled for December 22, 2025.

  • Berry Corporation Transaction: Berry Corporation shareholders will have their shares converted into 0.0718 shares of California Resources common stock, with a shareholder vote on December 15, 2025.

  • Evoke Pharma and First Savings Financial Group Sales: Evoke Pharma shareholders will receive $11.00 per share in cash from QOL Medical, while First Savings Financial Group shares will convert into 0.85 shares of First Merchants common stock, with respective deadlines for action on December 15 and December 19, 2025.

[object Object]
Preview
7.0
11-27WSJ
Gambling Firms Caution About Profit Decline Due to U.K. Tax Hikes

  • Impact of Tax Increases: Gambling companies like Flutter Entertainment and Entain anticipate reduced earnings due to the U.K. government's plans to increase taxes on online gambling operators.

  • Budget Measures: The U.K. budget includes higher levies for online gambling while offering some relief for betting shops, as part of efforts to improve public finances.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Evoke Pharma Inc (EVOK) stock price today?

The current price of EVOK is 10.94 USD — it has increased 0.09 % in the last trading day.

arrow icon

What is Evoke Pharma Inc (EVOK)'s business?

Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.

arrow icon

What is the price predicton of EVOK Stock?

Wall Street analysts forecast EVOK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVOK is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Evoke Pharma Inc (EVOK)'s revenue for the last quarter?

Evoke Pharma Inc revenue for the last quarter amounts to 4.28M USD, increased 61.40 % YoY.

arrow icon

What is Evoke Pharma Inc (EVOK)'s earnings per share (EPS) for the last quarter?

Evoke Pharma Inc. EPS for the last quarter amounts to -0.45 USD, decreased -52.13 % YoY.

arrow icon

What changes have occurred in the market's expectations for Evoke Pharma Inc (EVOK)'s fundamentals?

The market is revising No Change the revenue expectations for Evoke Pharma, Inc. (EVOK) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 109.98%.
arrow icon

How many employees does Evoke Pharma Inc (EVOK). have?

Evoke Pharma Inc (EVOK) has 3 emplpoyees as of December 05 2025.

arrow icon

What is Evoke Pharma Inc (EVOK) market cap?

Today EVOK has the market capitalization of 18.84M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free